Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Solovax
- Development stage
- Discontinued
- Lead developer
- Theriva Biologics
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Solovax is an autologous T-cell vaccine developed for the treatment of multiple sclerosis (MS). The therapeutic approach involves collecting myelin-reactive T-cells from a patient's peripheral blood, expanding them in vitro, and then attenuating them via irradiation. When reintroduced into the patient, these inactivated T-cells are intended to trigger an immune response against the patient's own pathogenic, myelin-reactive T-cells, thereby reducing the autoimmune attack on the central nervous system. The drug was developed by Pipex Therapeutics (which became Adeona Pharmaceuticals), but development appears to have ceased after 2008.
- Brand names
- Solovax
Beyond the preview
Go deeper on Solovax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solovax.